TW202110869A - 修飾之病毒顆粒及其用途 - Google Patents
修飾之病毒顆粒及其用途 Download PDFInfo
- Publication number
- TW202110869A TW202110869A TW109117155A TW109117155A TW202110869A TW 202110869 A TW202110869 A TW 202110869A TW 109117155 A TW109117155 A TW 109117155A TW 109117155 A TW109117155 A TW 109117155A TW 202110869 A TW202110869 A TW 202110869A
- Authority
- TW
- Taiwan
- Prior art keywords
- aav
- protein
- amino acid
- acid sequence
- capsid protein
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 183
- 230000003612 virological effect Effects 0.000 title description 34
- 241000288906 Primates Species 0.000 claims abstract description 384
- 210000000234 capsid Anatomy 0.000 claims abstract description 141
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 108090000565 Capsid Proteins Proteins 0.000 claims description 829
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 827
- 108090000623 proteins and genes Proteins 0.000 claims description 531
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 500
- 102000004169 proteins and genes Human genes 0.000 claims description 475
- 239000002773 nucleotide Substances 0.000 claims description 263
- 125000003729 nucleotide group Chemical group 0.000 claims description 263
- 230000027455 binding Effects 0.000 claims description 226
- 150000007523 nucleic acids Chemical class 0.000 claims description 159
- 241000700605 Viruses Species 0.000 claims description 136
- 108020004707 nucleic acids Proteins 0.000 claims description 112
- 102000039446 nucleic acids Human genes 0.000 claims description 112
- 101150044789 Cap gene Proteins 0.000 claims description 93
- 241000282320 Panthera leo Species 0.000 claims description 83
- 210000004027 cell Anatomy 0.000 claims description 80
- 230000035772 mutation Effects 0.000 claims description 61
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 51
- 241000270322 Lepidosauria Species 0.000 claims description 50
- 230000004048 modification Effects 0.000 claims description 46
- 238000012986 modification Methods 0.000 claims description 46
- 238000004806 packaging method and process Methods 0.000 claims description 40
- 230000008685 targeting Effects 0.000 claims description 31
- 230000010415 tropism Effects 0.000 claims description 31
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims description 28
- 101150066583 rep gene Proteins 0.000 claims description 27
- 239000003446 ligand Substances 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 241000271566 Aves Species 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 18
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 15
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 15
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 10
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 claims description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 8
- 108700008625 Reporter Genes Proteins 0.000 claims description 8
- 239000005090 green fluorescent protein Substances 0.000 claims description 8
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 7
- 108010082025 cyan fluorescent protein Proteins 0.000 claims description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 6
- 108010021843 fluorescent protein 583 Proteins 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 210000002706 plastid Anatomy 0.000 claims description 6
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 5
- 108091005941 EBFP Proteins 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 claims description 4
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 claims description 4
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 4
- 239000005089 Luciferase Substances 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 4
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 108091005943 CyPet Proteins 0.000 claims description 3
- 241000545067 Venus Species 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 108010054624 red fluorescent protein Proteins 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 229910052594 sapphire Inorganic materials 0.000 claims description 3
- 239000010980 sapphire Substances 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 239000004055 small Interfering RNA Substances 0.000 claims 3
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 241000579895 Chlorostilbon Species 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 229910052876 emerald Inorganic materials 0.000 claims 2
- 239000010976 emerald Substances 0.000 claims 2
- 108091005944 Cerulean Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 235000012736 patent blue V Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 7
- 238000011277 treatment modality Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 394
- 101710132601 Capsid protein Proteins 0.000 description 284
- 101710197658 Capsid protein VP1 Proteins 0.000 description 284
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 284
- 101710108545 Viral protein 1 Proteins 0.000 description 284
- 101710081079 Minor spike protein H Proteins 0.000 description 238
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 212
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 212
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 212
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 212
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 212
- 235000001014 amino acid Nutrition 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 19
- 230000009870 specific binding Effects 0.000 description 13
- 102000025171 antigen binding proteins Human genes 0.000 description 11
- 108091000831 antigen binding proteins Proteins 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 108091008324 binding proteins Proteins 0.000 description 8
- 210000004602 germ cell Anatomy 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 108010000916 Fimbriae Proteins Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000009126 molecular therapy Methods 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000649045 Adeno-associated virus 10 Species 0.000 description 2
- 241000649046 Adeno-associated virus 11 Species 0.000 description 2
- 241000649047 Adeno-associated virus 12 Species 0.000 description 2
- 241000300529 Adeno-associated virus 13 Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 101000856234 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) Butyrate-acetoacetate CoA-transferase subunit A Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 102100020744 Immunoglobulin iota chain Human genes 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852791P | 2019-05-24 | 2019-05-24 | |
| US62/852,791 | 2019-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202110869A true TW202110869A (zh) | 2021-03-16 |
Family
ID=71094822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109117155A TW202110869A (zh) | 2019-05-24 | 2020-05-22 | 修飾之病毒顆粒及其用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220241430A1 (enExample) |
| EP (1) | EP3976631A1 (enExample) |
| JP (3) | JP2022533438A (enExample) |
| KR (1) | KR20220011664A (enExample) |
| CN (2) | CN113874386A (enExample) |
| AR (2) | AR118997A1 (enExample) |
| AU (1) | AU2020283537A1 (enExample) |
| BR (1) | BR112021023692A2 (enExample) |
| CA (1) | CA3140386A1 (enExample) |
| CL (2) | CL2021003096A1 (enExample) |
| CO (1) | CO2021017692A2 (enExample) |
| IL (1) | IL288233A (enExample) |
| MA (1) | MA56035A (enExample) |
| MX (1) | MX2021014338A (enExample) |
| PE (1) | PE20212357A1 (enExample) |
| PH (1) | PH12021552887A1 (enExample) |
| SG (1) | SG11202112917PA (enExample) |
| TW (1) | TW202110869A (enExample) |
| WO (1) | WO2020242984A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12421525B2 (en) | 2018-02-28 | 2025-09-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Conjugates comprising AAVs and CAS9 polypeptides |
| AU2020283537A1 (en) * | 2019-05-24 | 2021-12-16 | Regeneron Pharmaceuticals, Inc. | Modified viral particles and uses thereof |
| US20240124892A1 (en) * | 2021-03-02 | 2024-04-18 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Adeno-associated viruses and methods and materials for making and using adeno-associated viruses |
| US20250195693A1 (en) * | 2021-04-30 | 2025-06-19 | Duke University | Compositions Comprising Adeno-Associated Virus Chimera Capsid Proteins and Methods of Using the Same |
| EP4359550A1 (en) * | 2021-06-23 | 2024-05-01 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| AU2023269134A1 (en) | 2022-05-09 | 2024-12-12 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| EP4766849A2 (en) * | 2023-08-24 | 2026-07-01 | Ohio State Innovation Foundation | Dosages and quality control methods for genome encapsidation for gene therapy purposes |
| CN121794393A (zh) * | 2023-09-07 | 2026-04-03 | 里珍纳龙药品有限公司 | 经共价表面修饰的腺相关病毒的生产和纯化 |
| WO2025111473A1 (en) * | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
| WO2026112457A2 (en) * | 2024-11-21 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6261554B1 (en) * | 1995-07-25 | 2001-07-17 | Introgene B.V. | Compositions for targeted gene delivery |
| AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| DE69936104T2 (de) | 1998-11-05 | 2008-01-17 | The Trustees Of The University Of Pennsylvania | Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten |
| CN103589692B (zh) * | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| EP2158211B1 (en) | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| WO2011072204A1 (en) | 2009-12-10 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| GB201002362D0 (en) | 2010-02-11 | 2010-03-31 | Isis Innovation | Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds |
| ES2926774T3 (es) * | 2013-03-15 | 2022-10-28 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores AAV de doble unión de glicano |
| WO2015137802A1 (en) * | 2014-03-10 | 2015-09-17 | Uniqure Ip B.V. | Further improved aav vectors produced in insect cells |
| AU2015230938C1 (en) | 2014-03-21 | 2021-10-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| US10577627B2 (en) * | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10550405B2 (en) * | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| EP4706687A3 (en) | 2017-06-27 | 2026-07-15 | Regeneron Pharmaceuticals, Inc. | Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells |
| SI3645551T1 (sl) | 2017-06-27 | 2024-06-28 | Regeneron Pharmaceuticals, Inc. | S tropizmi spremenjeni rekombinantni virusni vektorji in njihova uporaba za tarčni vnos genetskega materiala v človeške celice |
| US12421525B2 (en) * | 2018-02-28 | 2025-09-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Conjugates comprising AAVs and CAS9 polypeptides |
| AU2020283537A1 (en) * | 2019-05-24 | 2021-12-16 | Regeneron Pharmaceuticals, Inc. | Modified viral particles and uses thereof |
-
2020
- 2020-05-22 AU AU2020283537A patent/AU2020283537A1/en active Pending
- 2020-05-22 PE PE2021001934A patent/PE20212357A1/es unknown
- 2020-05-22 SG SG11202112917PA patent/SG11202112917PA/en unknown
- 2020-05-22 CN CN202080038612.3A patent/CN113874386A/zh active Pending
- 2020-05-22 CA CA3140386A patent/CA3140386A1/en active Pending
- 2020-05-22 BR BR112021023692A patent/BR112021023692A2/pt unknown
- 2020-05-22 PH PH1/2021/552887A patent/PH12021552887A1/en unknown
- 2020-05-22 JP JP2021569402A patent/JP2022533438A/ja active Pending
- 2020-05-22 TW TW109117155A patent/TW202110869A/zh unknown
- 2020-05-22 EP EP20733099.4A patent/EP3976631A1/en active Pending
- 2020-05-22 KR KR1020217041074A patent/KR20220011664A/ko active Pending
- 2020-05-22 MA MA056035A patent/MA56035A/fr unknown
- 2020-05-22 CN CN202210622571.3A patent/CN114989267A/zh active Pending
- 2020-05-22 US US17/612,669 patent/US20220241430A1/en active Pending
- 2020-05-22 AR ARP200101465A patent/AR118997A1/es unknown
- 2020-05-22 WO PCT/US2020/034328 patent/WO2020242984A1/en not_active Ceased
- 2020-05-22 MX MX2021014338A patent/MX2021014338A/es unknown
-
2021
- 2021-11-18 IL IL288233A patent/IL288233A/en unknown
- 2021-11-19 AR ARP210103220A patent/AR124119A2/es unknown
- 2021-11-23 CL CL2021003096A patent/CL2021003096A1/es unknown
- 2021-12-22 CO CONC2021/0017692A patent/CO2021017692A2/es unknown
-
2023
- 2023-03-03 CL CL2023000629A patent/CL2023000629A1/es unknown
-
2024
- 2024-11-11 JP JP2024196799A patent/JP2025032110A/ja active Pending
-
2025
- 2025-05-22 JP JP2025085876A patent/JP2025119015A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112917PA (en) | 2021-12-30 |
| CL2023000629A1 (es) | 2023-10-20 |
| WO2020242984A9 (en) | 2021-01-14 |
| JP2025032110A (ja) | 2025-03-11 |
| MX2021014338A (es) | 2022-01-06 |
| US20220241430A1 (en) | 2022-08-04 |
| PE20212357A1 (es) | 2021-12-17 |
| AR118997A1 (es) | 2021-11-17 |
| KR20220011664A (ko) | 2022-01-28 |
| IL288233A (en) | 2022-01-01 |
| EP3976631A1 (en) | 2022-04-06 |
| MA56035A (fr) | 2022-04-06 |
| BR112021023692A2 (pt) | 2022-01-04 |
| WO2020242984A1 (en) | 2020-12-03 |
| JP2025119015A (ja) | 2025-08-13 |
| CL2021003096A1 (es) | 2022-09-20 |
| CO2021017692A2 (es) | 2022-01-17 |
| CA3140386A1 (en) | 2020-12-03 |
| PH12021552887A1 (en) | 2022-09-05 |
| AU2020283537A1 (en) | 2021-12-16 |
| JP2022533438A (ja) | 2022-07-22 |
| CN113874386A (zh) | 2021-12-31 |
| AR124119A2 (es) | 2023-02-15 |
| CN114989267A (zh) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220241430A1 (en) | Modified viral particles and uses thereof | |
| JP7851839B2 (ja) | 遺伝物質をヒト細胞に標的化して導入するための指向性改変組換えウイルスベクターおよびその使用 | |
| US20250304918A1 (en) | Viral particles retargeted to skeletal muscle | |
| JP2025525792A (ja) | トランスフェリン受容体１に対して再標的化されるウイルス粒子 | |
| WO2026039325A2 (en) | Modified mtm1 genes and uses thereof | |
| RU2842439C2 (ru) | Модифицированные вирусные частицы и пути их применения | |
| WO2026025058A1 (en) | Aav viral particles retargeted to egfr-expressing cancer cells | |
| HK40112774A (en) | Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells | |
| HK40018460B (en) | Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells | |
| HK40018460A (en) | Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells | |
| BR122023021213B1 (pt) | Composição para o redirecionamento de proteínas do capsídeo viral |